OrganiGram Holdings Inc. (OGI)
USD 1.47
(-8.7%)
USD 1.47
(-8.7%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.7 Million CAD | 10.4% |
| 2022 | 3.35 Million CAD | -32.33% |
| 2021 | 4.96 Million CAD | -95.21% |
| 2020 | 103.67 Million CAD | 109.12% |
| 2019 | 49.57 Million CAD | -50.01% |
| 2018 | 99.16 Million CAD | 2718.52% |
| 2017 | 3.51 Million CAD | -53.04% |
| 2016 | 7.49 Million CAD | 54.18% |
| 2015 | 4.85 Million CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 136 Thousand CAD | -97.12% |
| 2024 Q3 | 100 Thousand CAD | -15.25% |
| 2024 Q2 | 118 Thousand CAD | -13.24% |
| 2023 Q3 | 180 Thousand CAD | -9.09% |
| 2023 Q1 | 217 Thousand CAD | -93.54% |
| 2023 Q2 | 198 Thousand CAD | -8.76% |
| 2023 FY | 4.71 Million CAD | 40.57% |
| 2023 Q4 | 4.71 Million CAD | 2521.67% |
| 2022 Q1 | 3.15 Million CAD | -36.42% |
| 2022 Q2 | 7.84 Million CAD | 148.73% |
| 2022 Q3 | 7.58 Million CAD | -3.31% |
| 2022 FY | 3.35 Million CAD | -32.33% |
| 2022 Q4 | 3.35 Million CAD | -55.74% |
| 2021 Q2 | 3.51 Million CAD | -97.05% |
| 2021 Q3 | 5.22 Million CAD | 48.69% |
| 2021 Q4 | 4.96 Million CAD | -5.11% |
| 2021 FY | 4.96 Million CAD | -95.21% |
| 2021 Q1 | 119.04 Million CAD | 14.83% |
| 2020 Q3 | 88.19 Million CAD | 1.4% |
| 2020 Q2 | 86.98 Million CAD | 0.72% |
| 2020 Q1 | 86.36 Million CAD | 74.2% |
| 2020 Q4 | 103.67 Million CAD | 17.55% |
| 2020 FY | 103.67 Million CAD | 109.12% |
| 2019 Q4 | 49.57 Million CAD | 0.22% |
| 2019 FY | 49.57 Million CAD | -50.01% |
| 2019 Q3 | 49.46 Million CAD | -20.57% |
| 2019 Q2 | 62.27 Million CAD | -36.91% |
| 2019 Q1 | 98.72 Million CAD | -0.45% |
| 2018 Q4 | 99.16 Million CAD | 0.48% |
| 2018 FY | 99.16 Million CAD | 2718.52% |
| 2018 Q1 | 3.4 Million CAD | -3.17% |
| 2018 Q2 | 96.28 Million CAD | 2726.47% |
| 2018 Q3 | 98.68 Million CAD | 2.49% |
| 2017 Q1 | 3.74 Million CAD | -50.05% |
| 2017 Q2 | 3.64 Million CAD | -2.63% |
| 2017 FY | 3.51 Million CAD | -53.04% |
| 2017 Q3 | 3.57 Million CAD | -2.0% |
| 2017 Q4 | 3.51 Million CAD | -1.47% |
| 2016 FY | 7.49 Million CAD | 54.18% |
| 2016 Q3 | 7.57 Million CAD | -1.02% |
| 2016 Q2 | 7.64 Million CAD | 3.14% |
| 2016 Q1 | 7.41 Million CAD | 52.62% |
| 2016 Q4 | 7.49 Million CAD | -1.04% |
| 2015 Q1 | 2.47 Million CAD | 0.0% |
| 2015 FY | 4.85 Million CAD | 0.0% |
| 2015 Q4 | 4.85 Million CAD | 102.05% |
| 2015 Q3 | 2.4 Million CAD | -1.75% |
| 2015 Q2 | 2.44 Million CAD | -1.21% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Theratechnologies Inc. | 58.96 Million USD | 93.715% |
| Harrow Health, Inc. | 190.5 Million USD | 98.055% |
| Dynavax Technologies Corporation | 256.91 Million USD | 98.557% |
| Biofrontera Inc. | 5.39 Million USD | 31.358% |
| Cronos Group Inc. | 2.53 Million USD | -45.909% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -509.539% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 99.482% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 89.797% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -215.94% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | 79.89% |
| Radius Health, Inc. | 365.31 Million USD | 98.986% |
| Universe Pharmaceuticals INC | 5.48 Million USD | 32.403% |
| DURECT Corporation | 20.74 Million USD | 82.136% |
| ProPhase Labs, Inc. | 21.38 Million USD | 82.666% |
| Safety Shot Inc | 1.54 Million USD | -139.255% |
| Phibro Animal Health Corporation | 525.45 Million USD | 99.295% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -39.983% |
| Alvotech | 1.07 Billion USD | 99.655% |
| Assertio Holdings, Inc. | 40.91 Million USD | 90.942% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 91.076% |
| Rockwell Medical, Inc. | 13.43 Million USD | 72.424% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -463.475% |
| Procaps Group S.A. | 285.93 Million USD | 98.704% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | 78.12% |
| SCYNEXIS, Inc. | 15.08 Million USD | 75.424% |
| Aytu BioPharma, Inc. | 15.12 Million USD | 75.504% |
| Viatris Inc. | 18.12 Billion USD | 99.98% |
| OptiNose, Inc. | 131.74 Million USD | 97.187% |
| SIGA Technologies, Inc. | 1.46 Million USD | -153.141% |
| Tilray Brands, Inc. | 387.31 Million USD | 99.043% |
| PetIQ, Inc. | 468.3 Million USD | 99.209% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -463.475% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 99.135% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Alimera Sciences, Inc. | 67.39 Million USD | 94.501% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 99.45% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -240.721% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 96.895% |
| Journey Medical Corporation | 17.73 Million USD | 79.098% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | 55.223% |
| Alpha Teknova, Inc. | 30.45 Million USD | 87.832% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | -77.575% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 97.157% |
| PainReform Ltd. | 86 Thousand USD | -4209.302% |
| Cosmos Health Inc. | 12.42 Million USD | 70.171% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | 89.526% |
| TherapeuticsMD, Inc. | 8 Million USD | 53.704% |
| Embecta Corp. | 1.63 Billion USD | 99.774% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -6096.599% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 99.368% |
| Incannex Healthcare Limited | 373 Thousand USD | -893.566% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -258.721% |
| Shineco, Inc. | 29.65 Million USD | 87.504% |
| Procaps Group, S.A. | 285.93 Million USD | 98.704% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 98.825% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 96.25% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 99.399% |
| Alvotech | 1.07 Billion USD | 99.655% |
| Hempacco Co., Inc. | 13.72 Million USD | 72.997% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | 94.067% |
| Bright Green Corporation | 1.85 Million USD | -100.131% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 99.315% |
| Kamada Ltd. | 8.74 Million USD | 57.641% |
| Indivior PLC | 281.6 Million USD | 98.684% |
| Evoke Pharma, Inc. | 5 Million USD | 25.88% |
| Flora Growth Corp. | 3.67 Million USD | -0.926% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -258.721% |
| Evolus, Inc. | 126.54 Million USD | 97.071% |
| HUTCHMED (China) Limited | 86.13 Million USD | 95.697% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 99.406% |
| Akanda Corp. | 3.99 Million USD | 7.322% |